Riskpilot← Back to searchSign inGet full accessOSLO DERMATOLOGY AS
ASActiveOrg 812603612Hegdehaugsveien 36B, 0352 OsloBuying and selling of own real estate · NACE 6811Est. 20133 employees
Revenue 2024
NOK 9,3M
-2% vs 2023
EBITDA margin
55.3%
+1% vs 2023
Equity ratio
83.3%
Financial strength
Net profit 2024
NOK 3,4M
+3% vs 2023
| Revenue | NOK 9,3M | -2% |
| EBITDA | NOK 5,1M | +1% |
| Net profit | NOK 3,4M | +3% |
| Total assets | NOK 34,9M | +7% |
| Equity | NOK 29,1M | +14% |
| Employees | 3 | — |
Legal name
OSLO DERMATOLOGY AS
Org number
812603612
Legal form
Aksjeselskap
NACE code
6811 · Buying and selling of own real estate
Founded
22. oktober 2013
Share capital
NOK 30 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Gry wigre
Company purpose
Kjøp, salg og utleie av eiendom til selskaper og privatpersoner.
Address
Hegdehaugsveien 36B, 0352 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 8 001 | 8 955 | 9 273 | 9 447 | 9 277 |
| Staff expenses | −1 138 | −1 193 | −1 184 | −1 002 | −842 |
| EBITDA | 3 705 | 4 595 | 4 804 | 5 060 | 5 128 |
| Depreciation & amort. | −411 | −399 | −394 | −392 | −759 |
| EBIT | 3 294 | 4 196 | 4 410 | 4 668 | 4 370 |
| Net financials | −73 | −56 | −337 | −393 | −121 |
| Profit before tax | 3 221 | 4 140 | 4 073 | 4 275 | 4 249 |
| Tax | 728 | 930 | 917 | 962 | 853 |
| Net profit | 2 493 | 3 210 | 3 156 | 3 312 | 3 396 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 24 550 | 22 420 | 33 939 | 32 730 | 34 916 |
| Equity | 16 734 | 19 044 | 22 200 | 25 513 | 29 100 |
| Long-term debt | 6 553 | 2 055 | 10 336 | 5 854 | 4 310 |
| Short-term debt | 1 263 | 1 321 | 1 402 | 1 363 | 1 506 |
| Total debt | 7 816 | 3 376 | 11 739 | 7 217 | 5 816 |
EBITDA margin
55.3%
This company
15.8%
Market median
+250% vs market
20202024
Equity ratio
83.3%
This company
38.2%
Market median
+118% vs market
20202024
Return on equity
11.7%
This company
18.4%
Market median
+36% vs market
20202024
Net profit margin
36.6%
This company
8.1%
Market median
+352% vs market
20202024
Asset turnover
0.27×
This company
1.12×
Market median
-76% vs market
20202024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MT Chief Executive Officer | Chief Executive Officer | 2013 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2013 | |
| Board of Directors | 2013 | |
| Chairman | 2013 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
OSLO DERMATOLOGY AS 
TIGALON HOLDING ASBoard members of OSLO DERMATOLOGY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maya Tigalonova-Waliszewska | Chief Executive Officer | 0 companies |
| Georg Tigalonov-Bjerke | Board of Directors | 0 companies |
| Georg Storaker Tigalonov-Bjerke | Board of Directors | 0 companies |
| Jens Roar Bjerke | Chairman | 0 companies |